Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening Program

      Background & Aims

      The latest generation of fecal immunochemical tests (FIT) allows for quantitation of hemoglobin in feces, allowing for selection of optimal cut-off concentrations. We investigated whether individuals with positive results from quantitative FITs, in combination with other factors, could be identified as being at greatest risk for advanced colorectal neoplasia.


      In a retrospective study, we analyzed data from a consecutive series of 3109 participants with positive results from FITs (≥20 μg/g of feces) included in the first round of the Barcelona colorectal cancer screening program, from December 2009 through February 2012. All participants underwent colonoscopy and were assigned to groups with any advanced colorectal neoplasia or with nonadvanced colorectal neoplasia (but with another diagnosis or normal examination findings).


      Median fecal hemoglobin concentrations were significantly higher in participants with advanced colorectal neoplasia (105 μg/g; interquartile range, 38–288 μg/g) compared with participants with nonadvanced colorectal neoplasia (47 μg/g; interquartile range, 23–119 μg/g) (P < .001). Positive predictive values for advanced colorectal neoplasia, determined using arbitrary fecal hemoglobin concentrations, differed with sex and age. Multivariate logistic regression analysis identified sex (men: odds ratio [OR], 2.07; 95% confidence interval, 1.78–2.41), age (60–69 y: OR, 1.24; 95% confidence interval, 1.07–1.44), and fecal hemoglobin concentration (>177 μg/g: OR, 3.80; 95% confidence interval, 3.07–4.71) as independent predictive factors for advanced colorectal neoplasia. Combining these factors, we identified 16 risk categories associated with different probabilities of identifying advanced colorectal neoplasia. Risk for advanced colorectal neoplasia increased 11.46-fold among individuals in the highest category compared with the lowest category; positive predictive values ranged from 21.3% to 75.6%.


      Fecal hemoglobin concentration, in addition to sex and age, in individuals with positive results from FITs can be used to stratify probability for the detection of advanced colorectal neoplasia. These factors should be used to prioritize individuals for colonoscopy examination.


      Abbreviations used in this paper:

      FIT (fecal immunochemical test), PPV (positive predictive value)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jemal A.
        • Bray F.
        • Center M.M.
        • et al.
        Global cancer statistics.
        CA Cancer J Clin. 2011; 61: 69-90
        • Cunningham D.
        • Atkin W.
        • Lenz H.J.
        • et al.
        Colorectal cancer.
        Lancet. 2010; 375: 1030-1047
        • Soreide K.
        • Nedrebo B.S.
        • Knapp J.C.
        • et al.
        Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist.
        Surg Oncol. 2009; 18: 31-50
        • Hardcastle J.D.
        • Thomas W.M.
        • Chamberlain J.
        • et al.
        Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects.
        Lancet. 1989; 1: 1160-1164
        • Jorgensen O.D.
        • Kronborg O.
        • Fenger C.
        A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds.
        Gut. 2002; 50: 29-32
        • Mandel J.S.
        • Church T.R.
        • Ederer F.
        • et al.
        Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.
        J Natl Cancer Inst. 1999; 91: 434-437
        • Guittet L.
        • Bouvier V.
        • Mariotte N.
        • et al.
        Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.
        Gut. 2007; 56: 210-214
        • Hol L.
        • Wilschut J.A.
        • van Ballegooijen M.
        • et al.
        Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels.
        Br J Cancer. 2009; 100: 1103-1110
        • Hol L.
        • de Jonge V.
        • van Leerdam M.E.
        • et al.
        Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy.
        Eur J Cancer. 2010; 46: 2059-2066
        • Park D.I.
        • Ryu S.
        • Kim Y.H.
        • et al.
        Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
        Am J Gastroenterol. 2010; 105: 2017-2025
        • Raginel T.
        • Puvinel J.
        • Ferrand O.
        • et al.
        A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
        Gastroenterology. 2013; 144: 918-925
        • van Rossum L.G.
        • van Rijn A.F.
        • Laheij R.J.
        • et al.
        Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
        Gastroenterology. 2008; 135: 82-90
        • Whitlock E.P.
        • Lin J.S.
        • Liles E.
        • et al.
        Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force.
        Ann Intern Med. 2008; 149: 638-658
        • van Rossum L.G.
        • van Rijn A.F.
        • Laheij R.J.
        • et al.
        Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme.
        Br J Cancer. 2009; 101: 1274-1281
        • Canard J.M.
        • Debette-Gratien M.
        • Dumas R.
        • et al.
        A prospective national study on colonoscopy and sigmoidoscopy in 2000 in France.
        Gastroenterol Clin Biol. 2005; 29: 17-22
        • Tappenden P.
        • Chilcott J.
        • Eggington S.
        • et al.
        Option appraisal of population-based colorectal cancer screening programmes in England.
        Gut. 2007; 56: 677-684
        • Terhaar sive Droste J.S.
        • Craanen M.E.
        • Kolkman J.J.
        • et al.
        Dutch endoscopic capacity in the era of colorectal cancer screening.
        Neth J Med. 2006; 64: 371-373
        • Kanavos P.
        • Schurer W.
        The dynamics of colorectal cancer management in 17 countries.
        Eur J Health Econ. 2010; 10: S115-S129
        • Castells A.
        • Castellvi-Bel S.
        • Balaguer F.
        Concepts in familial colorectal cancer: where do we stand and what is the future?.
        Gastroenterology. 2009; 137: 404-409
      1. Hospital Clinic, Parc de Salut Mar, Col.legi de Farmaceutics de Barcelona. Programa de detecció precoç de càncer de còlon i recte: Barcelona Esquerra-Litoral Mar. Pla Funcional. Barcelona: 2010.

        • Pinol V.
        • Castells A.
        • Andreu M.
        • et al.
        Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
        JAMA. 2005; 293: 1986-1994
        • Levin B.
        • Lieberman D.A.
        • McFarland B.
        • et al.
        Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.
        Gastroenterology. 2008; 134: 1570-1595
        • Segnan N.
        • Patnick J.
        • von Karsa L.
        European guidelines for quality assurance in colorectal cancer screening and diagnosis.
        Publications Office of the European Union, Luxembourg2010
        • Hassan C.
        • Quintero E.
        • Dumonceau J.M.
        • et al.
        Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
        Endoscopy. 2013; 45: 842-851
        • Sobin L.H.
        • Gospodarowicz M.
        • Wittekind C.
        TNM classification of malignant tumours.
        7th ed. Wiley-Blackwell, New York2009
        • Fraser C.G.
        • Allison J.E.
        • Young G.P.
        • et al.
        A standard for Faecal Immunochemical TesTs for Haemoglobin Evaluation Reporting (FITTER).
        Ann Clin Biochem. 2014; 51: 301-302
        • Fraser C.G.
        • Allison J.E.
        • Halloran S.P.
        • et al.
        A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin.
        J Natl Cancer Inst. 2012; 104: 810-814
        • Levi Z.
        • Rozen P.
        • Hazazi R.
        • et al.
        A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
        Ann Intern Med. 2007; 146: 244-255
        • Vilkin A.
        • Rozen P.
        • Levi Z.
        • et al.
        Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.
        Am J Gastroenterol. 2005; 100: 2519-2525
        • Hosmer D.W.
        • Lemeshow S.
        A goodness-of-fit test for the multiple logistic regression model.
        Commun Stat. 1980; A10: 1043-1069
        • Fraser C.G.
        • Allison J.E.
        • Young G.P.
        • et al.
        Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening.
        Clin Gastroenterol Hepatol. 2013; 11: 839-840
        • Ciatto S.
        • Martinelli F.
        • Castiglione G.
        • et al.
        Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme.
        Br J Cancer. 2007; 96: 218-221
        • Digby J.
        • Fraser C.G.
        • Carey F.A.
        • et al.
        Faecal haemoglobin concentration is related to severity of colorectal neoplasia.
        J Clin Pathol. 2013; 66: 415-419
        • Edwards J.B.
        Screening for colorectal cancer using faecal blood testing: varying the positive cut-off value.
        Pathology. 2005; 37: 565-568
        • Fraser C.G.
        • Mathew C.M.
        • McKay K.
        • et al.
        Automated immunochemical quantitation of haemoglobin in faeces collected on cards for screening for colorectal cancer.
        Gut. 2008; 57: 1256-1260
        • Grazzini G.
        • Visioli C.B.
        • Zorzi M.
        • et al.
        Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening?.
        Br J Cancer. 2009; 100: 259-265
        • Liao C.S.
        • Lin Y.M.
        • Chang H.C.
        • et al.
        Application of quantitative estimates of fecal hemoglobin concentration for risk prediction of colorectal neoplasia.
        World J Gastroenterol. 2013; 19: 8366-8372
        • Rozen P.
        • Comaneshter D.
        • Levi Z.
        • et al.
        Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
        Cancer. 2010; 116: 2115-2125
        • Wilschut J.A.
        • Habbema J.D.
        • van Leerdam M.E.
        • et al.
        Fecal occult blood testing when colonoscopy capacity is limited.
        J Natl Cancer Inst. 2011; 103: 1741-1751
        • Castiglione G.
        • Grazzini G.
        • Miccinesi G.
        • et al.
        Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood.
        J Med Screen. 2002; 9: 99-103
        • Hamza S.
        • Dancourt V.
        • Lejeune C.
        • et al.
        Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer.
        Eur J Cancer. 2013; 49: 2727-2733
        • Stegeman I.
        • de Wijkerslooth T.R.
        • Stoop E.M.
        • et al.
        Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy.
        Gut. 2014; 63: 466-471
        • Haggar F.A.
        • Boushey R.P.
        Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors.
        Clin Colon Rectal Surg. 2009; 22: 191-197
        • McDonald P.J.
        • Strachan J.A.
        • Digby J.
        • et al.
        Faecal haemoglobin concentrations by gender and age: implications for population-based screening for colorectal cancer.
        Clin Chem Lab Med. 2012; 50: 935-940
        • Kolligs F.T.
        • Crispin A.
        • Munte A.
        • et al.
        Risk of advanced colorectal neoplasia according to age and gender.
        PLoS One. 2011; 6: e20076
        • Quintero E.
        • Castells A.
        • Bujanda L.
        • et al.
        Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening.
        N Engl J Med. 2012; 366: 697-706
        • Hanley J.A.
        Analysis of mortality data from cancer screening studies: looking in the right window.
        Epidemiology. 2005; 16: 786-790
        • Driver J.A.
        • Gaziano J.M.
        • Gelber R.P.
        • et al.
        Development of a risk score for colorectal cancer in men.
        Am J Med. 2007; 120: 257-263
        • Freedman A.N.
        • Slattery M.L.
        • Ballard-Barbash R.
        • et al.
        Colorectal cancer risk prediction tool for white men and women without known susceptibility.
        J Clin Oncol. 2009; 27: 686-693
        • Omata F.
        • Shintani A.
        • Isozaki M.
        • et al.
        Diagnostic performance of quantitative fecal immunochemical test and multivariate prediction model for colorectal neoplasms in asymptomatic individuals.
        Eur J Gastroenterol Hepatol. 2011; 23: 1036-1041
        • Chen L.S.
        • Yen A.M.
        • Fraser C.G.
        • et al.
        Impact of faecal haemoglobin concentration on colorectal cancer mortality and all-cause death.
        BMJ Open. 2013; 3: e003740
        • Castells A.
        • Bessa X.
        • Quintero E.
        • et al.
        Risk of advanced proximal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-based strategies.
        J Natl Cancer Inst. 2013; 105: 878-886